Medical/Pharmaceuticals
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 08:30
1868
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE
NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th ...
2025-12-15 22:10
3095
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesit...
2025-12-15 21:00
2588
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation,
clinical alignment, and GMP-grade excellence acrossSoutheast Asia
SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan
2025-12-15 17:00
2000
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, in...
2025-12-15 17:00
7096
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...
2025-12-15 15:02
1713
Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice
HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration inHong Kong that will provide customer...
2025-12-15 13:45
2802
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, out...
2025-12-15 12:40
2635
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in
the inauguralFortune Best Companies to Work For Southeast Asia 2025 list, in
partnership with Great Place To Work®, highlighting workplaces acrossSingapore,
Malaysia, Thailand and the Philippines.
2025-12-15 09:00
7034
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: * Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. * The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CY...
2025-12-15 08:25
1860
ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion
SEOUL, South Korea, Dec. 13, 2025 /PRNewswire/ -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant...
2025-12-13 08:00
3320
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as th...
2025-12-12 00:21
2956
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-bindin...
2025-12-11 23:57
2849
ProPharma Expands Operations with New Office in Hyderabad
Modern workspace supports continued growth and innovation
RALEIGH, N.C., Dec. 11, 2025 /PRNewswire/ -- ProPharma
2025-12-11 21:10
1477
MATELASER W1 REGEN: The Lightest 24g and Highest 5,100 mW/cm² Wearable Red Light Therapy Device Debuts on Kickstarter
MIAMI, Dec. 11, 2025 /PRNewswire/ -- MATELASER, INC., a pioneer in mobile laser therapy, today announced the official launch of its global crowdfunding campaign for the W1 REGEN, a breakthrough device that brings clinic-grade laser therapy into an ultra-miniature 24g wearable form. Priced at just...
2025-12-11 20:30
1686
The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) Opens in Hong Kong: AI Technology and Digital Health Usher in a New Chapter of Translational Medicine.
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Cerebro-cardiovascular conditions have continued to pose a public health burden. The convergence of population ageing and lifestyle risk factors has made "earlier detection, earlier intervention, and accessible and affordable prevention and management" a c...
2025-12-11 19:19
2230
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...
2025-12-11 14:12
2390
Rhinocare Korea Accelerates Global Expansion with Singapore Joint Venture
K-Healthtech Firm Targets Rapid Global Scale-Up with Drug-Free Nasal-Care Innovation SINGAPORE and SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ -- Rhinocare Korea, a medtech innovator specializing in drug-free respiratory care, announced plans to establish a joint venture (JV) inSingapore as p...
2025-12-11 12:46
3296
Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southernChina, carrying profound historical heritage and unique clinical value.The Seventh World Hakka Entrepreneurs Conven...
2025-12-11 08:00
1598
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...
2025-12-11 03:30
2014
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 318 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 256 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 250 media titles]
2026-02-16 08:00